Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of combining trastuzumab with combination
chemotherapy in treating patients who have locally recurrent or metastatic urinary tract
cancer. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them
or deliver tumor-killing substances to them without harming normal cells. Drugs used in
chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die. Combining monoclonal antibody therapy with combination chemotherapy may kill more tumor
cells